The Swiss voice in the world since 1935

Hefty fines against Swiss pharma giants lifted

man applying eye drops
Age-related macular degeneration is an eye disease that can blur your central vision. It happens when aging causes damage to the macula — the part of the eye that controls sharp, straight-ahead vision. (Symbolic photo) Keystone / Martin Ruetschi

An appeals court in France has overturned a record fine imposed by the French competition authority against the Swiss pharmaceutical companies Novartis and Roche.

The verdict was announced by a court in Paris on Thursday.

Both firms were given a fine totaling €444 million (CHF438.9 million) in 2020 for following allegedly abusive practices, notably in the sale of the eye disease drug Lucentis at the expense of the Avastin drug treatment, which is up to 30 times cheaper.

Novartis was accused of conducting a communication campaign from 2008 to 2013 to discredit the use of Avastin in ophthalmology. The company was therefore fined the highest amount, €385 million, while Roche and its US subsidiary Genentech were fined €59 million.

In a first reaction, Novartis and Roche said they were “pleased” with the decision. They have denied allegations from the outset, arguing they acted appropriately in accordance with competition law and in the interests of patients at all times, according to the Swiss AWP news agency.

Different conclusion

The Paris court ruled that Avastin should be considered as no longer on the market from the time new legislation for the treatment of age-related macular degeneration came into effect in 2011.

The judges found that Novartis’ communications during the period under review were “moderate in tone”. They also found that the two companies’ communications had not been “alarmist or even misleading”.

Finally, the court held that the blocking behaviour of Roche, which had refused to provide Avastin samples requested by the health authorities for the launch of a scientific study, could not have had anti-competitive effects.

+ Will hefty price tags of the treatments make them unaffordable?

Popular Stories

Most Discussed

News

Plane grazes hikers on Monte Rosa, pilot apologises

More

Plane grazes hikers on Monte Rosa

This content was published on A Geneva-registered tourist plane grazed some ski mountaineers on Saturday on a glacier on the Swiss side of the Monte Rosa massif.

Read more: Plane grazes hikers on Monte Rosa
The air in climbing gyms is more polluted than on the streets

More

Air in climbing gyms more polluted than on streets

This content was published on The concentration of potentially harmful chemicals in climbing gyms is sometimes higher than on busy roads, say researchers from Switzerland and Austria.

Read more: Air in climbing gyms more polluted than on streets
Swiss with lower profit in the first quarter

More

SWISS reports lower profit in first quarter

This content was published on Swiss International Air Lines (SWISS) achieved slightly higher sales at the start of the year. However, profits fell sharply, partly due to the late Easter.

Read more: SWISS reports lower profit in first quarter
Significantly less wine is drunk in Switzerland

More

Swiss drink significantly less wine

This content was published on Wine consumption in Switzerland fell by almost 8% in 2024 compared to the previous year. Swiss wines are particularly affected by the decline.

Read more: Swiss drink significantly less wine

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR